Literature DB >> 15994220

Current treatments of epilepsy.

Siddhartha Nadkarni1, Josiane LaJoie, Orrin Devinsky.   

Abstract

Medical therapy is the mainstay for epilepsy, with most patients well controlled on a single antiepileptic drug (AED). In this non-refractory group, many patients have medication side effects and occasional seizures. Approximately 30% of patients with partial epilepsy and 25% of patients with generalized epilepsy are not well controlled on medications. These patients are often receiving multiple AEDs, with disabling seizures and side effects. Although second-generation AEDs are safer and better tolerated than the older AEDs, there are scant data to support significant advantages in efficacy. In VA studies with older AEDS, therapy with two AEDs improved seizure control in 40% of patients but seizure freedom was achieved in only 9%. A meta-analysis of the second-generation AEDs used as adjunctive therapies shows that 12% to 29% of patients had a 50% or greater reduction in seizure frequency. Surgery and the vagus nerve stimulator provide important therapeutic options in patients whose seizures are not controlled by AEDs. Special considerations about epilepsy care must be made in pediatric populations, those with developmental delays, women, and the elderly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994220     DOI: 10.1212/wnl.64.12_suppl_3.s2

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

Review 1.  Gene therapy for epilepsy.

Authors:  David W McCandless; Jeffrey W McCandless
Journal:  Metab Brain Dis       Date:  2010-09-23       Impact factor: 3.584

2.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

Review 3.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

4.  High frequency stimulation can suppress globally seizures induced by 4-AP in the rat hippocampus: an acute in vivo study.

Authors:  Chia-Chu Chiang; Chou-Ching K Lin; Ming-Shaung Ju; Dominique M Durand
Journal:  Brain Stimul       Date:  2012-05-15       Impact factor: 8.955

5.  Role of KCC2-dependent potassium efflux in 4-Aminopyridine-induced Epileptiform synchronization.

Authors:  Oscar C González; Zahra Shiri; Giri P Krishnan; Timothy L Myers; Sylvain Williams; Massimo Avoli; Maxim Bazhenov
Journal:  Neurobiol Dis       Date:  2017-10-16       Impact factor: 5.996

6.  Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA.

Authors:  Maciej Gasior; Natalie A White; Michael A Rogawski
Journal:  J Pharmacol Exp Ther       Date:  2007-08-23       Impact factor: 4.030

7.  Role of multidrug transporters in neurotherapeutics.

Authors:  Manna Jose; Sanjeev V Thomas
Journal:  Ann Indian Acad Neurol       Date:  2009-04       Impact factor: 1.383

Review 8.  Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation.

Authors:  Detlev Boison; Kerry-Ann Stewart
Journal:  Biochem Pharmacol       Date:  2009-08-12       Impact factor: 5.858

9.  Use of antiepileptic drugs for hyperkinetic movement disorders.

Authors:  A Siniscalchi; L Gallelli; G De Sarro
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

10.  Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects.

Authors:  Erik K St Louis
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.